Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV002512239 | SCV002821223 | pathogenic | not provided | 2022-10-01 | criteria provided, single submitter | clinical testing | GYG1: PVS1, PM2 |
Labcorp Genetics |
RCV002569453 | SCV003525291 | pathogenic | Glycogen storage disease XV; Polyglucosan body myopathy type 2 | 2022-10-16 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs777291159, gnomAD 0.004%). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with clinical features of glycogen storage disease (PMID: 29264399). This sequence change creates a premature translational stop signal (p.Arg216*) in the GYG1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GYG1 are known to be pathogenic (PMID: 20357282, 25272951). |